bluebird bio Inc. (BLUE) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

bluebird bio Inc. (BLUE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

8.03

-0.46 (-5.42%)

At close: Jan 14, 2025, 3:59 PM

8.01

-0.19%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	7
Market Cap	78.02M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-36
PE Ratio (ttm)	-0.22
Forward PE	n/a
Analyst	Hold

Ask	8.49
Volume	177,404
Avg. Volume (20D)	412,488
Open	8.49
Previous Close	8.49
Day's Range	7.96 - 8.75
52-Week Range	5.80 - 38.40
Beta	undefined

About BLUE

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinic...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 19, 2013

Employees 375

Stock Exchange NASDAQ

Ticker Symbol BLUE

Website https://www.bluebirdbio.com

Analyst Forecast

According to 9 analyst ratings, the average rating for BLUE stock is "Hold." The 12-month stock price forecast is $36.8, which is an increase of 358.57% from the latest price.

Buy 22.22%

Hold 66.67%

Sell 11.11%

Stock Forecasts

Why Price Moved

1 month ago · Source

+105.44%

Bluebird Bio shares are trading higher after the c... Unlock content with Pro Subscription

1 month ago · Source

+2.16%

bluebird bio shares are trading lower after the FDA announced an investigation into a serious risk of hematologic malignancy following Skysona.

News

1 month ago · businesswire.com

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced new and updated data from LYFGENIA™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickl...

1 month ago · businesswire.com

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data from patients with beta-thalassemia who require regular blood transfusions treated with betibeglogene...

1 month ago · businesswire.com

ISS Recommends Dye & Durham Shareholders Vote the BLUE Proxy Card “FOR” Three of Engine Capital's Directors, Including Proposed Chair and Interim CEO Hans Gieskes

NEW YORK--(BUSINESS WIRE)--Engine Capital LP (together with its affiliates, "Engine" or "we"), which owns approximately 7.1% of the issued and outstanding common shares of Dye & Durham Limited (TSX: D...

1 month ago · businesswire.com

bluebird bio Announces 1-for-20 Reverse Stock Split

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it will proceed with a 1-for-20 reverse stock split (“Reverse Stock Split”)...

1 month ago · businesswire.com

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has reached an agreement with the Center for Medicare and Medicaid Innovation to offer an outc...

1 month ago · reuters.com

FDA investigates risk of blood cancers from bluebird bio's gene therapy

The U.S. Food and Drug Administration said on Wednesday it is investigating reports of blood cancers in patients who were treated with bluebird bio's gene therapy Skysona.

1 month ago · businesswire.com

BLUE OWL CAPITAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Blue Owl Capital Corporation III - OBDE

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Blue Owl Capit...

1 month ago · seekingalpha.com

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

Investment activity in October focused on Business Development Companies, with $1,300 added to the market. Adjusted dividend income in October of $789, up 25% Y/Y and up 11% sequentially. Main picks i...

2 months ago · benzinga.com

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

On Thursday, Bluebird Bio Inc. BLUE reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents.

2 months ago · proactiveinvestors.com

bluebird bio downgraded by Bank of America, shares tumble

bluebird bio Inc (NASDAQ:BLUE) shares shed more than 11% on Friday after the Massachusetts-based biotech company developing gene therapies for severe genetic diseases was downgraded by Bank of America...

2 months ago · seekingalpha.com

bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript

bluebird bio, Inc. (NASDAQ:BLUE ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director, Investor Relations Andrew Obenshain - Chief Executive ...

2 months ago · zacks.com

Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates

Bluebird Bio (BLUE) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.66 per share a year ago.

2 months ago · zacks.com

After Plunging -22.76% in 4 Weeks, Here's Why the Trend Might Reverse for Bluebird (BLUE)

The heavy selling pressure might have exhausted for Bluebird (BLUE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i...

2 months ago · businesswire.com

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio presenting data from gene therapy programs in Sickle Cell Disease and Beta-Thalassemia at the 66th ASH Annual Meeting and Exposition.